Lumos Diagnostics Holdings Limited

Equities

LDX

AU0000157091

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. Other stock markets 02:10:33 2024-06-05 am EDT			5-day change	1st Jan Change
0.033 ^AUD	-10.81%		-8.33%	-54.79%

Jun. 04	Lumos Diagnostics Receives Second Payment Under IP Agreement; Shares Up 8%	MT
May. 06	Lumos Diagnostics Concludes Initial Phase of Development Deal with Hologic for Fetal Fibronectin Test; Shares Jump 6%	MT

Lumos Diagnostics Holdings Limited Announces Appoints Rob Sambursky to the Role of Chief Medical Officer

April 10, 2022 at 07:26 pm EDT

Lumos Diagnostics Holdings Limited announced Rob Sambursky has transitioned to the role of Chief Medical Officer in which he will focus on Lumos' clinical affairs and support for the Company's commercial operations.

Latest news about Lumos Diagnostics Holdings Limited

Lumos Diagnostics Receives Second Payment Under IP Agreement; Shares Up 8%	Jun. 03	MT
Lumos Diagnostics Concludes Initial Phase of Development Deal with Hologic for Fetal Fibronectin Test; Shares Jump 6%	May. 05	MT
Lumos Diagnostics' FebriDx May Help Optimize Antibiotic Use in Children with Febrile Respiratory Infections, Study Shows	Apr. 08	MT
Lumos Diagnostics Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Lumos Diagnostics Hires Henry Schein as US Distributor for Respiratory Infection Blood Test; Shares Rise 4%	Feb. 11	MT
Lumos Diagnostics' Q4 Revenue Jumps 55%	Jan. 31	MT
Australian Shares Rise Ahead of US Inflation Data	Jan. 11	MT
Lumos Diagnostics Signs Development and IP Agreements with Hologic; Shares Up 24%	Jan. 10	MT
Lumos Signs Major Development and IP Agreements with Hologic, Inc	Jan. 10	CI
Lumos Diagnostics Raises AU$2.7 Million to Support US Launch of FebriDx, ViraDx; Shares Down 6%	23-10-29	MT
US FDA Grants Emergency Use Authorization for Lumos Diagnostics' ViraDx	23-09-11	MT
Lumos Diagnostics Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
Lumos Diagnostics Secures Europe, Japan Patents for Core Camera Reader	23-08-16	MT
Lumos Diagnostics Expands FebriDx Market to Netherlands	23-08-16	MT
Lumos Diagnostics Announces Core Camera Reader Patent Granted in Europe and Japan	23-08-15	CI
Lumos Diagnostics Secures R&D Tax Rebate for Fiscal Year 2022	23-08-10	MT
Lumos Diagnostics Signs Partnership with Henry Schein Medical for FebriDx Distribution; Shares Jump 8%	23-07-17	MT
Lumos Diagnostics Holdings Limited Appoints Doug Ward to Board as Managing Director	23-07-12	CI
Lumos Diagnostics Secures US FDA Clearance for Bacterial Respiratory Infection Test	23-07-03	MT
Lumos Diagnostics Secures AU$9 Million in Funding from New Agreements With US Healthcare Company	23-03-16	MT
Lumos Diagnostics Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26	CI
Lumos Diagnostics Wins Two Service Agreements from Health Company Hologic	22-11-23	MT
Lumos Diagnostics Secures Two Service Agreements with Hologic	22-11-22	CI
Lumos Diagnostics Holdings Limited announced that it expects to receive AUD 8 million in funding from SBC Global Investors, The Lind Partners, LLC	22-11-20	CI
Lumos Diagnostics Reports Higher Revenue in Fiscal Q1	22-10-28	MT

Chart Lumos Diagnostics Holdings Limited

Duration

Period

Chart Lumos Diagnostics Holdings Limited

More charts

Company Profile

Lumos Diagnostics Holdings Ltd is an Australia-based company, which specializes in point-of-care (POC) diagnostic test technology to help healthcare professionals diagnose and manage medical conditions. The Company offers customized assay development and manufacturing services for POC tests and digital reader platforms. It also directly develops, manufactures, and commercializes, Lumos-branded POC tests that target infectious and inflammatory diseases. The Companyâs products include FEBRIDX, COVIDX, and ViraDx. FebriDx is a point-of-care test which can be used to detect and aid in differentiating bacterial from viral acute respiratory infections. ViraDx is a point-of-care, three-in-one COVID-19/Flu A/Flu B rapid antigen test. Its services include assay development, reader development, cloud and data, and manufacturing. It manages the full development program for point-of-care (POC) assays, from sourcing and/or generation of reagents, right through to verification and validation.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-19 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
LUMOS DIAGNOSTICS HOLDINGS LIMITED	-54.79%	11.84M
BIOMÉRIEUX	-5.37%	12.35B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.75%	8.17B
DIASORIN S.P.A.	+7.79%	5.77B
LANTHEUS HOLDINGS, INC.	+33.10%	5.65B
AUTOBIO DIAGNOSTICS CO., LTD.	-12.12%	4.1B
ANDON HEALTH CO., LTD.	+14.18%	2.67B
VITROLIFE AB	-5.70%	2.31B
MYRIAD GENETICS, INC.	+18.60%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-6.70%	1.81B

Diagnostic & Testing Substances